These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 24300522)

  • 1. Efficient panel designs for longitudinal recurrent event studies recording panel counts.
    Juarez-Colunga E; Dean CB; Balshaw R
    Biostatistics; 2014 Apr; 15(2):234-50. PubMed ID: 24300522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Joint monitoring and prediction of accrual and event times in clinical trials.
    Zhang X; Long Q
    Biom J; 2012 Nov; 54(6):735-49. PubMed ID: 22907686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Semiparametric regression analysis for recurrent event interval counts.
    Staniswalis JG; Thall PF; Salch J
    Biometrics; 1997 Dec; 53(4):1334-53. PubMed ID: 9423253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blinded and unblinded internal pilot study designs for clinical trials with count data.
    Schneider S; Schmidli H; Friede T
    Biom J; 2013 Jul; 55(4):617-33. PubMed ID: 23703749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conditional analysis of mixed Poisson processes with baseline counts: implications for trial design and analysis.
    Cook RJ; Wei W
    Biostatistics; 2003 Jul; 4(3):479-94. PubMed ID: 12925513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Semiparametric transformation models for panel count data with correlated observation and follow-up times.
    Li N; Zhao H; Sun J
    Stat Med; 2013 Jul; 32(17):3039-54. PubMed ID: 23297190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of statistical issues with progression-free survival as an interval-censored time-to-event endpoint.
    Sun X; Li X; Chen C; Song Y
    J Biopharm Stat; 2013; 23(5):986-1003. PubMed ID: 23957511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increasing trial efficiency by early reallocation of placebo nonresponders in sequential parallel comparison designs: application to antidepressant trials.
    Boessen R; Knol MJ; Groenwold RH; Grobbee DE; Roes KC
    Clin Trials; 2012 Oct; 9(5):578-87. PubMed ID: 23060319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regression analysis of multivariate panel count data.
    He X; Tong X; Sun J; Cook RJ
    Biostatistics; 2008 Apr; 9(2):234-48. PubMed ID: 17626224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crossover versus parallel designs: dose-escalation design comparisons for first-in-human studies.
    Yan Z; Hosmane B; Locke C
    J Biopharm Stat; 2013; 23(4):804-17. PubMed ID: 23786490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ECNP consensus meeting. Bipolar depression. Nice, March 2007.
    Goodwin GM; Anderson I; Arango C; Bowden CL; Henry C; Mitchell PB; Nolen WA; Vieta E; Wittchen HU
    Eur Neuropsychopharmacol; 2008 Jul; 18(7):535-49. PubMed ID: 18501566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of the 1990 Hong Kong legislation for restriction on sulfur content in fuel.
    Wong CM; Rabl A; Thach TQ; Chau YK; Chan KP; Cowling BJ; Lai HK; Lam TH; McGhee SM; Anderson HR; Hedley AJ
    Res Rep Health Eff Inst; 2012 Aug; (170):5-91. PubMed ID: 23316618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The design of a panel study under an alternating Poisson process assumption.
    Albert PS; Brown CH
    Biometrics; 1991 Sep; 47(3):921-32. PubMed ID: 1742446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of baseline covariates on the efficiency of statistical analyses of crossover designs.
    Yan Z
    Stat Med; 2013 Mar; 32(6):956-63. PubMed ID: 22903413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On the efficiency of two-stage response-adaptive designs.
    Dette H; Bornkamp B; Bretz F
    Stat Med; 2013 May; 32(10):1646-60. PubMed ID: 22865374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal and efficient crossover designs under different assumptions about the carryover effects.
    Hedayat AS; Stufken J
    J Biopharm Stat; 2003 Aug; 13(3):519-28. PubMed ID: 12921398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modelling and design of cross-over trials.
    Jones B; Donev AN
    Stat Med; 1996 Jul; 15(13):1435-46. PubMed ID: 8841653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blinded sample size re-estimation for recurrent event data with time trends.
    Schneider S; Schmidli H; Friede T
    Stat Med; 2013 Dec; 32(30):5448-57. PubMed ID: 24105855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On the designs of thorough QT/QTc clinical trials.
    Tsong Y
    J Biopharm Stat; 2013; 23(1):43-56. PubMed ID: 23331220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analyzing counts, durations, and recurrences in clinical trials.
    McIntosh J
    J Biopharm Stat; 2001; 11(1-2):65-74. PubMed ID: 11459443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.